If you have been searching for a peptide therapeutics ETF the way you would search for a clean energy or semiconductor fund, here is the honest answer: one does not really exist yet. As of early 2026 there is no pure-play peptide ETF that gives you clean exposure to the peptide drug category the way an index fund gives you exposure to the S&P 500. What does exist is a growing set of obesity- and GLP-1-themed ETFs, plus broad biotech and pharma funds that happen to be heavily weighted toward peptide-drug developers. For most investors, that indirect route is currently the best way to play the theme.
This guide walks through the four realistic ways to get peptide exposure through funds, compares expense ratios and concentration, and flags the risks nobody prints on the marketing one-pager. This article is for educational purposes only and does not constitute investment advice.
Market Overview
The peptide therapeutics market — which includes GLP-1 obesity drugs, insulin and its analogs, octreotide, leuprolide, ziconotide, linaclotide, teduglutide, and dozens of oncology and rare-disease peptides — generated roughly $80–90 billion in global sales in 2024 and is on track to exceed $170 billion by 2030 according to most sell-side forecasts. Obesity GLP-1s account for the majority of that growth, but the category is broader than most investors realize: more than 100 peptide drugs are FDA-approved, and another 150+ are in clinical development.
The reason there is no dedicated peptide ETF is mechanical. Thematic ETFs need at least 25–40 investable names with meaningful revenue exposure to the theme. The peptide therapeutics universe is top-heavy: Novo Nordisk (NVO) and Eli Lilly (LLY) together represent more than 80% of category revenue and market cap. Any index you built would either look like a two-stock concentration bet or dilute itself with tangential names until it stopped being a peptide fund.
Until an issuer solves that problem, investors are left to assemble peptide exposure from four building blocks.
Key Funds and ETFs
The table below summarizes the main vehicles discussed in this article. Expense ratios and AUM are early-2026 approximate figures and move frequently — always confirm on the issuer's fact sheet.
| Fund | Ticker | Category | Expense Ratio | Peptide Exposure | Top Holdings Flavor |
|---|---|---|---|---|---|
| Tema GLP-1, Obesity & Cardiometabolic ETF | HRTS | Obesity thematic | ~0.75% | High | NVO, LLY, VKTX, AMGN |
| Roundhill GLP-1 & Weight Loss ETF | OZEM | Obesity thematic | ~0.59% | High | NVO, LLY, plus CDMOs and device names |
| SPDR S&P Biotech ETF | XBI | Broad biotech (equal-weight) | 0.35% | Medium | Equal-weight small/mid biotech |
| iShares Biotechnology ETF | IBB | Broad biotech (market-cap) | 0.45% | Medium-High | AMGN, GILD, VRTX, REGN |
| ARK Genomic Revolution ETF | ARKG | Genomics/biotech active | 0.75% | Low-Medium | Gene editing + select peptide names |
| Health Care Select Sector SPDR | XLV | Pharma mega-cap | 0.09% | Medium | LLY, JNJ, UNH, MRK |
| Invesco Dynamic Pharmaceuticals | PJP | Pharma thematic | ~0.56% | Medium | Rotating pharma |
1. Obesity-Themed ETFs: The Closest Thing to a Peptide Fund
Two dedicated obesity/GLP-1 ETFs launched in 2023–2024 and have become the de facto way to buy the theme.
Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS) is actively managed and explicitly targets companies developing or enabling cardiometabolic and weight-loss therapies. Because it is active, it can underweight the duopoly and tilt toward challengers like Viking Therapeutics (VKTX), Structure Therapeutics (GPCR), and Altimmune (ALT) when the manager sees value. It also holds supporting infrastructure — peptide CDMOs, device makers for auto-injectors, and continuous glucose monitor companies.
Roundhill GLP-1 & Weight Loss ETF (OZEM) is a passive, index-based fund. It follows a purpose-built benchmark of companies with material revenue or pipeline exposure to GLP-1 and obesity therapeutics. Its expense ratio is modestly lower than HRTS, and its concentration in NVO and LLY is typically higher because it weights by the index rules rather than a manager's view.
Both funds are small (AUM in the hundreds of millions rather than billions), which means bid-ask spreads are wider than on mega-ETFs and the issuer could, in theory, close the fund if flows never materialize. They are also effectively concentrated bets on Novo Nordisk and Eli Lilly — the combined NVO+LLY weight often exceeds 35–45%, so when those two stocks move, the ETF moves.
An Amplify Obesity ETF concept was floated in 2024 but had not launched at time of writing. If it does, it joins the list.
2. Broad Biotech ETFs With Heavy Peptide Exposure
If you want peptide exposure without tying yourself to the obesity narrative, broad biotech funds are the workhorse.
SPDR S&P Biotech ETF (XBI) is the benchmark US biotech ETF for small- and mid-cap names. It is equal-weighted, which means the smallest constituent has roughly the same influence as the largest on rebalance day. That structure gives XBI disproportionate exposure to clinical-stage peptide developers, oral GLP-1 plays, and takeout candidates — exactly the kind of names Viking Therapeutics was before it ran. XBI is the fund most commonly recommended to investors who want "the biotech trade" without picking stocks.
iShares Biotechnology ETF (IBB) is market-cap-weighted and therefore heavier in large-cap peptide-adjacent names like Amgen (AMGN), Vertex (VRTX), Regeneron (REGN), and Gilead (GILD). It gives you less small-cap upside but fewer white-knuckle drawdowns than XBI.
ARK Genomic Revolution ETF (ARKG) is more gene editing than peptide, but Cathie Wood's team has held selective peptide names when they intersect with the fund's rejuvenation and metabolic health theses. Expect low direct peptide weight and high volatility.
3. Pharma Mega-Cap ETFs
For the most conservative route, broad healthcare or pharma ETFs give you Eli Lilly exposure (often a top-three weight) alongside the rest of the sector.
Health Care Select Sector SPDR (XLV) is the largest and cheapest healthcare ETF at 0.09%. LLY is typically a top-three weight, putting roughly 10–12% of the fund behind the tirzepatide franchise. Novo Nordisk is not included because XLV is a US-only S&P 500 sector fund.
Invesco Dynamic Pharmaceuticals (PJP) and similar pharma-focused funds rotate among the major drug makers and generally include LLY at meaningful weights.
Note that neither XLV nor PJP gives you Novo Nordisk, because NVO trades as an ADR and is not in the S&P 500. International healthcare funds like iShares Global Healthcare (IXJ) and SPDR S&P International Health Care Sector (IRY) do include NVO.
4. Direct Stock Alternatives
The cleanest peptide exposure is still a curated basket of individual stocks. A rough DIY peptide portfolio might combine:
- Large cap anchors: Novo Nordisk (NVO), Eli Lilly (LLY)
- Challengers: Amgen (AMGN), Viking Therapeutics (VKTX), Structure Therapeutics (GPCR)
- CDMOs (pick-and-shovel): Bachem (BACN.SW), PolyPeptide Group (PPGN.SW), Lonza (LONN.SW)
- Optional: Altimmune (ALT), Terns Pharmaceuticals (TERN), Metsera (MTSR if trading)
This is more work and carries higher single-stock risk, but it lets you control concentration directly and avoid paying 0.59–0.75% per year in fund fees. For context on how DIY portfolio construction compares to ETF investing in the gene editing adjacent space, see our guide to gene editing investing ETFs and funds.
The Science Under the Hood
Peptide drugs are short amino acid chains that bind to cell-surface receptors with extreme specificity. That specificity is their commercial moat — fewer off-target effects than small molecules — but it comes with two manufacturing consequences that shape the investing landscape.
First, peptides have to be built one amino acid at a time using solid-phase peptide synthesis (SPPS) or expressed in engineered microbes. Both routes are expensive and slow compared to making a small-molecule pill, which is why the CDMO layer has become a genuine investment theme in its own right (covered separately in our peptide CDMO piece).
Second, peptides have short half-lives in the body and cannot usually be swallowed. The drugs that have gone blockbuster — semaglutide, tirzepatide, liraglutide — all use chemical tricks like fatty-acid acylation to stretch their half-life from minutes to days. That formulation IP is part of what makes the leaders defensible. If you want the biology foundations before going deeper, see natural peptides in the human body.
Investment Thesis & Risks
Bull Case for Thematic Peptide Exposure
- Category is still early in penetration. Global obesity treatment rates remain in single digits.
- Label expansion keeps adding TAM. Every new indication (sleep apnea, heart failure, MASH, Alzheimer's) increases the addressable market.
- Rising tide effect. Even middling challengers get acquired at premiums when the category is hot.
- CDMO and device exposure in some thematic ETFs adds a pick-and-shovel cushion.
Bear Case
- Concentration risk. Obesity-themed ETFs are really NVO+LLY funds wearing a costume. If either stock corrects, the ETF corrects harder than XBI would.
- Fee drag. 0.59–0.75% is expensive versus XLV at 0.09%, especially if the fund ends up just tracking two mega-caps.
- Theme fatigue. Thematic ETFs that track a single news cycle (cannabis, work-from-home, blockchain) have historically underperformed once the narrative matures.
- Liquidity. Small AUM means wider spreads and the risk the ETF gets liquidated if flows reverse.
- Gene editing disruption. A durable one-shot alternative to weekly peptide injections would reset the long-term earnings power of the whole category. Low probability, high impact.
What To Watch in 2026
- New issuances. Expect at least one more obesity ETF launch and possibly the first true "peptide therapeutics" branded fund if an issuer solves the diversification problem.
- AUM inflection. HRTS and OZEM crossing $1B in AUM would validate the theme and tighten spreads.
- Coverage decisions. Medicare, European payer, and PBM formulary decisions drive fundamentals more than any product launch.
- Retatrutide and orforglipron readouts. Big swings in thematic ETFs usually follow big swings in LLY.
- CDMO M&A. Further consolidation among peptide manufacturers would lift the pick-and-shovel weight inside some thematic ETFs.
- Compounding litigation. How the FDA and state boards handle compounded GLP-1s after shortage status is removed.
Connection to Gene Editing
Peptide therapeutics ETFs and gene editing ETFs look like different trades, but they are really two sides of the same long-term bet on molecular medicine. Peptide funds are a bet on protein signaling drugs scaling into one of the biggest therapeutic categories ever. Gene editing funds like ARKG, or any portfolio with CRISPR Therapeutics (CRSP), Intellia (NTLA), Beam (BEAM), Verve (VERV), and Prime Medicine (PRME), are a bet on rewriting the code that produces those proteins in the first place.
In the near term, peptide ETFs benefit from the cash flows those drugs are generating right now. In the long term, gene editing is the most credible threat to the weekly-injection business model — a one-time base editing treatment that reprograms the liver's metabolic set-point could do to GLP-1s what Casgevy is starting to do to chronic sickle cell management (see our Casgevy analysis). Sophisticated biotech investors hold both and rebalance depending on where they think the disruption window sits.
Frequently Asked Questions
Q: Is there a pure peptide therapeutics ETF? A: Not really. Obesity/GLP-1-themed ETFs like HRTS and OZEM are the closest available option. They effectively function as concentrated NVO + LLY + challenger baskets.
Q: What is the cheapest way to get Eli Lilly exposure through a fund? A: XLV at 0.09% holds LLY as a top-three weight. That is cheaper than any thematic obesity ETF, at the cost of diluting your exposure with the rest of the healthcare sector.
Q: How do I get Novo Nordisk exposure through a US-listed ETF? A: Global healthcare or international biotech funds (IXJ, IRY, IHI, MSCI Europe healthcare products). NVO is not in the S&P 500 and therefore not in XLV.
Q: Are obesity ETFs too concentrated to be safe? A: They are effectively two-stock bets dressed as a thematic fund. If that matches your thesis, fine. If you want diversification, a broad biotech ETF like XBI or IBB is a better structure.
Q: Should I buy the ETF or the stocks directly? A: If your conviction is specifically in NVO and LLY, owning them directly saves you 0.59–0.75% a year. An ETF makes more sense if you want automatic rebalancing, exposure to challengers you do not want to research individually, or if your broker does not offer direct access to Danish or Swiss-listed names.
